Evogene Ltd. · NASDAQ:EVGN
Evogene — Investor Presentation (January 2020)
24 slides from Evogene's investor presentation, Jan 28, 2020
Slide 1: Investor Presentation January 2020
INVESTOR PRESENTATAION January 2020
Slide 2: Safe Harbor Statement
2 SAFE HARBOR STATEMENT All written and oral forward - looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements . Except for any obligations to disclose information as required by applicable securities laws, Evogene di
Slide 3: Agenda
3 AGENDA What we do Evolution of Evogene Target markets Corporate structure & activities Summary Technological approach
Slide 4: What We Do
4 WHAT WE DO Evogene is a leading company in leveraging computational biology to design novel products for life - science - based industries including: human health, agriculture and industrial applications
Slide 5: Evolution of Evogene
Evo Plant gene traits Era Computational Era 2002 Established Evogene positioned as a world leading gene - trait company 2008 Computational Predictive Biology (CPB) platform established - expanding to genomics, chemistry and microbes Internal divisions are formed to establish a proof of concept to ta
Slide 6: The Challenge in Product Development
6 THE CHALLENGE IN PRODUCT DEVELOPMENT COMMON PRACTICE Product Launch Long time to market Product Definition Low probability of success High development costs Efficacy Stability Shelf - life Safety Limited ‘ next generation ’ products in pipelines Product candidates addressing mainly efficacy
Slide 7: Evogene's Solution: Candidates with the Highest Probability of Success
7 Product Definition Efficacy Stability Shelf - life Safety A. Computational prediction system for candidates addressing the majority of product criteria at Stage Zero EVOGENE ’ S SOLUTION CANDIDATES WITH THE HIGHEST PROBABILITY OF SUCCESS Successful Product Launch The CPB Platform B. Continuous sup
Slide 8: Evogene's Solution: Candidates with the Highest Probability of Success
8 EVOGENE ’ S SOLUTION CANDIDATES WITH THE HIGHEST PROBABILITY OF SUCCESS Increasing probability of success Reducing time to market Reducing budget A. Computational prediction system for candidates addressing the majority of product criteria at Stage Zero Successful Product Launch The CPB Platform B
Slide 9: CPB Platform – Why Now?
9 CPB PLATFORM – WHY NOW? HARNESSING THE POWER OF THE COMPUTATIONAL REVOLUTION Evogene ’ s CPB platform leveraging the revolutions in Big Data and Artificial Intelligence together with a deep understanding of biology, to successfully address multiple product attributes at the beginning of the discov
Slide 10: Fields of Development
10 FIELDS OF DEVELOPMENT Microbes Genetic Elements Small Molecules Plant genes – associated to specific plant traits Plant edits – edits to control gene expression Genomic markers – genomics tools to assist breeders Bacterial genes – toxins for insects Essential genes – target for herbicides ' /
Slide 11: Target Markets & Fields of Activity
11 TARGET MARKETS & FIELDS OF ACTIVITY Microbes Genetic Elements Small Molecules Prism Plant genes – associated to specific plant traits Plant edits – edits to control gene expression Genomic markers – genomics tools to assist breeders* Bacterial genes – toxins for insects Essential genes – target f
Slide 12: Evogene's Business Model Example: Lavie Bio
12 EVOGENE ’ S BUSINESS MODEL EXAMPLE LAVIE BIO – FROM AN IDEA TO PRODUCTS CPB stage Division stage Tech - hub & subsidiary stage Product Launch Establish computational & validation infrastructure for product development Initiate product pipeline as proof - of - concept Expanding pipeline & advancem
Slide 13: From a Division to a Subsidiary
13 FROM A DIVISION TO A SUBSIDIARY Microbes Genetic Elements Small Molecules Prism Plant genes – associated to specific plant traits Plant edits – edits to control gene expression Genomic markers – genomics tools to assist breeders* Bacterial genes – toxins for insects Essential genes – target for h
Slide 14: Company Structure
14 COMPANY STRUCTURE Field Collaborations Bio Stimulants Bio Pesticides ( i ) Yield, ABST (ii) Plant Disease (iii) Insect Control ( i ) Stable high yield of specific compounds (ii) Stable high yield of total compounds ( i ) Immuno - oncology (ii) MDRO (iii) GI related disorders Herbicides Insecticid
Slide 15: Corteva Investment in Lavie Bio
& CORTEVA Q searon agriscience WHO WE ARE ‘OUR IMPACT PRODUCTS & SERVICES BLOG MEDIA CENTER Home / Me ter / Corteva to Invest in Evogene’s Lavi Press Release * 8/7/2019 Corteva Agriscience to Invest in Evogene's Agriculture Biologicals lavie bio Subsidiary, Lavie Bio better by nature Investment Incl
Slide 16: Company Structure
16 COMPANY STRUCTURE Field Collaborations Bio Stimulants Bio Pesticides ( i ) Yield, ABST (ii) Plant Disease (iii) Insect Control ( i ) Stable high yield of specific compounds (ii) Stable high yield of total compounds ( i ) Immuno - oncology (ii) MDRO (iii) GI related disorders Herbicides Insecticid
Slide 17: Canonic Cannabis Cultivation and Breeding
C/ANONIC evogene Canonic Announces Initiation of Cultivation and Breeding of Cannabis Varieties with Unique Genomic Profiles for the Development of Medical Cannabis Products This announcement follows successfully importing a collection of widely genetically diverse cannabis lines, establishing speci
Slide 18: Company Structure
18 COMPANY STRUCTURE Field Collaborations Bio Stimulants Bio Pesticides ( i ) Yield, ABST (ii) Plant Disease (iii) Insect Control ( i ) Stable high yield of specific compounds (ii) Stable high yield of total compounds ( i ) Immuno - oncology (ii) MDRO (iii) GI related disorders Herbicides Insecticid
Slide 19: Biomica Agreement with Biose Industrie
BIOMICA evogene Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program The scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical tria
Slide 20: Milestone Roadmap 2020-2021
20 MILESTONE ROADMAP 2020 2021 Demonstrate first desired cannabis trait ( e.g yield or specific cannabinoid) File for regulatory approval for a wheat bio - stimulant product, and pre - commercialization phase advancement Receive regulatory approval and initiation of pre - commercial activities (pilo
Slide 21: Summary
21 SUMMARY We leverage computational biology to design novel products for life - science - based industries including human health, agriculture, and industrial applications. WHAT WE DO Utilizing artificial intelligence and other algorithms on unique biological BIG DATA with deep understanding of lif
Slide 22: Thank You
\ evogene THANK YOU
Slide 23: Annex I: Financial Fundamentals
23 Annex I: Financial Fundamentals
Slide 24: Key Financials – Balance Sheet
24 Thousand US $ 30.09.2019 31.12.2018 Current Assets 53,828 55,488 Long - Term Assets 22,615 * 3,206 Total Assets 76,443 58,694 Current Liabilities 4,729 5,431 Long - Term Liabilities 5,580 2,957 Equity attributable to equity holders of the Company 56,090 50,053 Non - controlling interest 10,044